Pelthos Therapeutics Inc
ir.pelthos.comWhat Do They Do?
Sells ZELSUVMI, a prescription topical treatment for molluscum contagiosum, to pharmaceutical wholesalers.
10-K for FY2025, filed Mar 19, 2026Pelthos Therapeutics Inc. (the “Company”) is a bio-pharmaceutical company committed to commercializing innovative, safe, and efficacious…View ↗
ZELSUVMI (berdazimer) topical gel, 10.3% is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum…View ↗
The Company primarily sells its ZELSUVMI product to national and regional wholesaler channels. Our wholesalers purchase products from us…View ↗
How Do They Make Money?
Wholesalers buy ZELSUVMI, and product sales are counted when it is delivered. A Japan license agreement also brings in upfront and other payments for licensed rights and development work, with development work counted as it progresses.
10-K for FY2025, filed Mar 19, 2026The Company currently sells ZELSUVMI to national and regional wholesalers in the United States. Revenue from product sales is recognized…View ↗
The Company concluded that Sato is a customer with respect to all promises in the Amended Sato Agreement, and as such, revenue is…View ↗
A portion of transaction price allocated to license performance obligation was recognized in revenues on the date of license delivery. For…View ↗
$16.8M
-
10-K for FY2025, filed Mar 19, 2026
$16.8M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net product revenues
Sold outright
10-K for FY2025, filed Mar 19, 2026 |
96% |
Net product revenues, FY2025
$16.2M Sources
|
Sold outright |
|
License and collaboration revenues
Licensed
|
3.5% |
License and collaboration revenues, FY2025
$589K Sources
|
Licensed |
Who Are Their Customers?
Pelthos sells ZELSUVMI to national and regional wholesalers, which supply products to retail drug store chains, independent pharmacies and mail order pharmacies.
10-K for FY2025, filed Mar 19, 2026The Company primarily sells its ZELSUVMI product to national and regional wholesaler channels. Our wholesalers purchase products from us…View ↗
10-K for FY2025, filed Mar 19, 2026
Financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash, cash equivalents…View ↗
Do Revenues Turn Into Profits?
No. It lost $43.3M in FY2025.
10-K for FY2025, filed Mar 19, 2026
−$32.4MView ↗
10-K for FY2025, filed Mar 19, 2026
−$43.3MView ↗
10-K for FY2025, filed Mar 19, 2026
−$22.7MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$23.4MView ↗
- ▲ +579% (Loss)
- vs −$3.4M in Q2 FY2025
-
Aug 13, 2026
Company will restate first-quarter financial statements
A convertible-debt fair-value accounting error led to the restatement; the company also identified a material weakness in its financial controls.
Sources
8-K, filed Aug 13, 2026
On August 12, 2026, the audit committee of our board of directors (the “Audit Committee”), in consultation with management, concluded that…View ↗
-
May 21, 2026
Company replaced its independent accounting firm
Grant Thornton was appointed after CBIZ was dismissed.
Sources
8-K, filed May 21, 2026
On May 16, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of Pelthos Therapeutics Inc. (the…View ↗
-
Apr 10, 2026
Company appointed a new CFO
John M. Gay succeeded Francis Knuettel II, effective April 10, 2026.
Sources
8-K, filed Apr 10, 2026
On April 6, 2026, the Board of Directors (the “Board”) of Pelthos Therapeutics Inc. (the “Company”) appointed John M. Gay, age 49, to serve…View ↗
Loading...
